Edwards strong Q3 propels shares to 10-year high
This article was originally published in Clinica
Executive Summary
On the eve of posting strong third-quarter financials, shares in Edwards Lifesciences leapt to their highest ever value on the NYSE. On October 20, the day before announcing its Q3results, Edwards’ shares peaked at $72.45 each, signalling its best pricing in nearly ten years as a publicly-listed firm.